Insmed Incorporated
0JAV.L
London Stock Exchange112.29
USD
+2.85
- -
Insmed Incorporated
0JAV.L
(London Stock Exchange)
Recent
price
112.29
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Insmed Incorporated (NASDAQ: INSM; LSE: 0JAV) is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases, particularly in pulmonary, inflammatory, and genetic conditions; its approved products include ARIKAYCE (amikacin liposome inhalation suspension) for refractory Mycobacterium avium complex (MAC) lung disease in adults with limited treatment options, approved on an accelerated basis by the U.S. FDA in 2018 with full approval in Europe and Japan, and BRINSUPRI (brensocatib), an oral reversible dipeptidyl peptidase 1 (DPP1) inhibitor approved for non-cystic fibrosis bronchiectasis; the company advances a diverse pipeline encompassing mid- to late-stage investigational medicines such as treprostinil palmitil inhalation powder (TPIP) in Phase 3 for pulmonary hypertension associated with interstitial lung diseases (PH-ILD) and Phase 2 for pulmonary arterial hypertension (PAH), brensocatib in Phase 2 for chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS), and INS1201 gene therapy in Phase 1 for Duchenne muscular dystrophy (DMD), alongside preclinical programs including gene therapies for amyotrophic lateral sclerosis (ALS) and Stargardt disease, next-generation DPP1 inhibitors like INS1033 for inflammatory bowel disease and rheumatoid arthritis, and other discovery efforts in multiple indications using technologies such as AI-driven protein engineering, RNA end-joining, and synthetic rescue. Founded in 1988 and headquartered in Bridgewater, New Jersey, Insmed operates through nine corporate offices and four global research sites across the United States, Europe (including offices in Utrecht, Netherlands, and a new research lab in Cambridge, UK), and Japan, where it established a subsidiary in 2017; the company targets patients with rare pulmonary diseases like nontuberculous mycobacterial lung disease, neutrophil-driven inflammatory disorders, and genetic conditions, serving markets in the U.S., Europe, Japan, and internationally with over 1,500 team members as of mid-2025. Recent developments include FDA approval of its second therapy in 2025, topline results from Phase 2b and Phase 3 studies in pulmonary arterial hypertension, PH-ILD, and bronchiectasis in 2024-2025, initiation of Phase 1 dosing for INS1201 in DMD in July 2025 with planned IND filings for ALS and Stargardt programs, a $150 million upsizing of its term loan facility with Pharmakon Advisors in October 2024 extending maturity to 2029 to support ARIKAYCE commercialization and brensocatib launch preparations, and a proposed $650 million public offering of common stock in June 2025 with an option for $97.5 million more to fund pipeline advancement and operations.